Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:NGM) to Strong Buy from Outperform with a price target of $39, up from $27,…
45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.
10 Biggest Price Target Changes For Monday
Keybanc lowered the price target on FedEx Corporation (NYSE: FDX) from $370 to $350. FedEx shares rose 0.6% to $259.00 in pre-market trading.
Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy, Raises Price Target to $39
Raymond James analyst Steven Seedhouse upgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Strong Buy and raises the price target from $27 to $39.
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831
Publication describes NGM's discovery of ILT3's functional ligand, fibronectin, a key component of the tumor stroma
ILT3-fibronectin interactions within the tumor microenvironment may form a stromal checkpoint